New York, New York--(Newsfile Corp. - January 22, 2026) - Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Semler Scientific (NASDAQ: SMLR) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at Semler Scientific caused the company to misrepresent or fail to disclose that: (1) Semler Scientific did not disclose a material investigation by the United States Department of Justice into violations of the False Claims Act, while discussing possible violations of the False Claims Act (and aggressive DOJ enforcement thereof) in hypothetical terms; and (2) as a result, the Company's public statements were materially false and/or misleading at all relevant times.
Semler Scientific Inc. (NASDAQ: SMLR - Get Free Report) has earned a consensus rating of "Moderate Buy" from the five brokerages that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 1 year price
Generali Asset Management SPA SGR lifted its position in Semler Scientific Inc. (NASDAQ: SMLR) by 42.9% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 100,000 shares of the company's stock after buying an additional 30,000 shares during the quarter. Generali Asset Management
Semler Scientific Inc. (NASDAQ: SMLR - Get Free Report) has been assigned an average rating of "Moderate Buy" from the five brokerages that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average 12 month target
Semler Scientific (NASDAQ: SMLR - Get Free Report) and Vasamed (OTCMKTS:VSMD - Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends. Earnings and Valuation This table compares Semler Scientific and
NEW YORK and NEW ORLEANS , Dec. 12, 2025 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
One of the hottest trends for crypto in 2025 is reversing. Among the US and Canadian-listed companies that became digital asset treasuries, or DATs, the median stock price has fallen 45% this year, according to data compiled by Bloomberg.
MONSEY, N.Y., Dec. 09, 2025 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed merger of Semler Scientific, Inc. (Nasdaq: SMLR) (“Semler”) with Strive Asset Management (“Strive”) in an all-stock transaction under which Semler stockholders will receive 21.05 shares of Strive Class A Common Stock for each share of Semler common stock that they own (“Exchange Ratio”).
CAMPBELL, Calif. , Oct. 28, 2025 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), the second U.S. public company to adopt Bitcoin as its primary treasury reserve asset and a leader in medical devices and software to combat chronic diseases, today announced that due to its pending transaction with Strive, Inc., the company will not be hosting a conference call or providing an accompanying earnings presentation in conjunction with its third quarter 2025 financial results.
NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Semler Scientific, Inc. ("Semler Scientific, Inc." or the "Company") (NASDAQ: SMLR) of a class action securities lawsuit.
